News about "Ionis Pharmaceuticals"

Ionis Reports Positive Phase 3 FUSION Study Results

Ionis reports positive phase 3 FUSION results for ulefnersen, advancing a potential first disease-modifying treatment for FUS-ALS.

Ionis Pharmaceuticals | 24/09/2026 | By News Bureau

US FDA Approves ZANVASTRO as First Disease-Modifying Treatment for Alexander Disease

The US Food and Drug Administration (FDA) approves ZANVASTRO (zilganersen) as the first disease-modifying treatment for Alexander Disease (AxD) in pediatric and adult patients.

Ionis Pharmaceuticals | 05/09/2026 | By News Bureau

Novartis Reports Phase 3 Results for Pelacarsen in Cardiovascular Disease

Novartis reports phase 3 Lp(a)HORIZON topline results for pelacarsen, an investigational ASO targeting Lp(a) production in patients with cardiovascular disease (CVD).

Ionis Pharmaceuticals | 05/09/2026 | By News Bureau |  142

AstraZeneca, Ionis' Wainua Misses Phase 3 Primary Endpoint in ATTR-CM Trial

AstraZeneca and Ionis reported that Wainua (eplontersen) missed the primary endpoint in the phase 3 CARDIO-TTRansform trial for ATTR-CM, while maintaining a consistent safety profile.

Ionis Pharmaceuticals | 10/07/2026 | By News Bureau |  173

Biogen Announces Topline Phase 2 Results for Diranersen in Early Alzheimer's Disease

Ionis partner Biogen announces topline phase 2 CELIA trial results for diranersen (BIIB080), showing reduced tau pathology and cognitive benefits in patients with early Alzheimer's Disease (AD).

Ionis Pharmaceuticals | 15/05/2026 | By News Bureau |  207

FDA Accepts Ionis' Zilganersen NDA for Priority Review in AxD

Ionis’ zilganersen NDA for Alexander disease has been accepted by the FDA for Priority Review, with a PDUFA target action date set for 22nd September, 2026, marking a key regulatory milestone for the potential treatment.

Ionis Pharmaceuticals | 24/03/2026 | By News Bureau |  329

Ionis Receives FDA Approval of New Drug Application for Donidalorsen

Donidalorsen is designed to reduce the production of prekallikrein (PKK), interrupting the pathway that leads to HAE attacks.

Ionis Pharmaceuticals | 06/11/2024 | By Aishwarya |  959

Ionis Pharmaceuticals plans California manufacturing site

At an expected 217,000 square feet, the site will be double the size of Ionis' current Carlsbad, California

Ionis Pharmaceuticals | 14/10/2022 | By Sudeep Soparkar |  713

ALS drug by Biogen and Ionis Pharmaceuticals fails in trials

Biogen and Ionis Pharmaceuticals were hoping to be the first to find a cure for ALS. That dream has now fizzled out with the companies calling it quits after receiving disappointing results from a phase 1 clinical trial.

Ionis Pharmaceuticals | 27/04/2022 | By Sudeep Soparkar |  782